Efficacy of Kegan Liyan oral liquid vs. Lianhuaqingwen capsules for patients with mild COVID-19: a double-blinded, randomized, controlled, non-inferiority trial

Efficacy of Kegan Liyan oral liquid vs. Lianhuaqingwen capsules for patients with mild COVID-19: a double-blinded, randomized, controlled, non-inferiority trial

BackgroundTraditional Chinese medicine has been used for Coronavirus disease 2019 (COVID-19) as a therapeutic option. Lianhuaqingwen capsules (LHQW) are well-recognized for their efficacy, while Kegan Liyan oral liquid (KGLY), widely used for influenza treatment, has emerged as a promising candidate...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuewei Li, Yihe Chi, Mengting Zhu, Feiting Fan, Zhongyang Deng, Jingmin Xiao, Shaohan Jin, Luoqi Lin, Xiaochun Chen, Ruhong Xu, Long Fan, Xuhua Yu, Ziyao Liang, Jingyu Quan, Shangzhao Li, Xinying Peng, Yuanbin Chen, Lin Lin, Lei Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Medicine
Subjects:
coronavirus disease 2019
Kegan Liyan oral liquid
Lianhuaqingwen capsules
non-inferiority
randomized controlled trial
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2025.1531370/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2025.1531370/full

Similar Items